# CranRichPAC (Vaccinium macrocarpon)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/cranrichpac
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-01
**Evidence Score:** 2 / 10
**Category:** Other
**Also Known As:** Vaccinium macrocarpon extract, American cranberry extract, Standardized cranberry PAC extract, Cranberry proanthocyanidin concentrate, Large cranberry extract, Bearberry cranberry, CranRich PAC

## Overview

CranRichPAC is a standardized cranberry extract (Vaccinium macrocarpon) concentrated in A-type proanthocyanidins (PACs), primarily tetramers (49%) and pentamers (37%), which inhibit P-fimbriated Escherichia coli from adhering to uroepithelial cell surfaces. This bacterial anti-adhesion mechanism, rather than direct [antimicrobial](/ingredients/condition/immune-support) activity, is the primary proposed pathway for its urinary tract health support.

## Health Benefits

• May support urinary tract health through bacterial anti-adhesion properties (evidence quality: indirect/general cranberry data only)
• Contains proanthocyanidins (tetramers 49%, pentamers 37%) with potential [antioxidant activity](/ingredients/condition/antioxidant) (evidence quality: chemical analysis only)
• Rich in organic acids including quinic (≥0.9%), citric (≥0.9%), and malic (≥0.7%) acids (evidence quality: compositional data)
• Contains triterpenoids like ursolic acid (372.97 mg/g) with [anti-inflammatory](/ingredients/condition/inflammation) potential (evidence quality: in vitro mechanisms)
• Provides phenolic compounds including epicatechin (2.45–4.46 mg/100g) and flavonols (evidence quality: analytical data only)

## Mechanism of Action

CranRichPAC's A-type proanthocyanidins (primarily tetramers and pentamers) interfere with the adhesion of P-fimbriated Escherichia coli to uroepithelial glycoprotein receptors, specifically blocking mannose-resistant hemagglutination pathways critical to bacterial colonization. The organic acids present, including quinic and citric acid, may mildly acidify urine, creating a less hospitable environment for bacterial proliferation. Additionally, the PAC fraction exhibits free-radical scavenging activity by donating hydrogen atoms to neutralize [reactive oxygen species](/ingredients/condition/antioxidant), though this antioxidant pathway is secondary to the anti-adhesion mechanism in the context of urinary health.

## Clinical Summary

Direct clinical evidence for CranRichPAC as a branded ingredient is limited, with available data largely extrapolated from general cranberry extract and cranberry juice trials rather than proprietary formulation studies. Meta-analyses of cranberry products in urinary tract infection (UTI) prevention, such as a 2012 Cochrane review of 24 studies (n=4,473), found modest but inconsistent reductions in symptomatic UTI recurrence, particularly in women with recurrent UTIs. A key challenge in interpreting this evidence is that PAC content and A-type linkage specificity vary widely across cranberry products, and CranRichPAC-specific randomized controlled trials with defined PAC dosages and quantified outcomes have not been published in peer-reviewed literature to date. The evidence quality for this ingredient currently remains indirect, derived from chemical characterization and class-level cranberry research.

## Nutritional Profile

CranRichPAC is a concentrated cranberry (Vaccinium macrocarpon) extract standardized primarily for proanthocyanidin (PAC) content rather than macronutrient delivery. Key compositional data: Proanthocyanidins are the primary bioactive fraction, consisting of tetramers (~49%) and pentamers (~37%), with smaller proportions of trimers and higher oligomers; total PAC content is standardized per batch (typically expressed as mg PAC per gram of extract using DMAC assay methodology). Organic acids are a defining feature: quinic acid (≥0.9%), citric acid (≥0.9%), and malic acid (≥0.7%) by weight, contributing to the characteristic tart profile and potential urinary pH modulation. Polyphenol broader profile includes flavonols (quercetin, myricetin glycosides), anthocyanins (cyanidin, peonidin, and delphinidin derivatives), and hydroxycinnamic acids (chlorogenic, caffeic acids) at trace-to-minor concentrations typical of dried cranberry extracts. Vitamin C is present in fresh cranberry (~13 mg/100g fruit) but concentration in this extract form is not standardized and likely variable depending on processing. Mineral content is minimal at typical extract doses; potassium, manganese, and copper are present in whole cranberry but are not primary features of this concentrated PAC fraction. Fiber and macronutrients are negligible at functional serving sizes of this extract. Bioavailability note: Cranberry PACs, particularly A-type linkage proanthocyanidins (characteristic of Vaccinium species and distinguishing them from grape/apple B-type PACs), have limited systemic absorption; primary activity is considered luminal/mucosal, particularly within the urinary tract epithelium via anti-adhesion mechanisms. Metabolites including phenolic acids (hippuric acid, benzoic acid derivatives) are detectable in urine following ingestion, confirming some degree of gut microbial [metabolism](/ingredients/condition/weight-management) and absorption.

## Dosage & Preparation

No clinically studied dosage ranges are available for CranRichPAC specifically. General cranberry extracts lack standardization specifics tied to trials. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

CranRichPAC is generally well tolerated at typical supplemental doses; the most commonly reported side effects from cranberry extracts include mild gastrointestinal discomfort, nausea, and diarrhea, particularly at higher doses. Clinically significant interaction with warfarin (Coumadin) has been documented for cranberry products broadly, with case reports and pharmacokinetic studies suggesting cranberry constituents may inhibit CYP2C9-mediated warfarin [metabolism](/ingredients/condition/weight-management), potentially elevating INR and bleeding risk; concurrent use warrants medical supervision. Individuals with a history of calcium oxalate kidney stones should exercise caution, as cranberry extracts can increase urinary oxalate excretion. Safety data in pregnancy and lactation is insufficient to make definitive recommendations, and consultation with a healthcare provider is advised before use during these periods.

## Scientific Research

No specific human clinical trials, RCTs, or meta-analyses were found for CranRichPAC in the available research. The EMA assessment report summarizes broader Vaccinium macrocarpon evidence but notes insufficient data for authoritative claims on UTIs or other conditions, with no study designs or outcomes specified for this branded form.

## Historical & Cultural Context

Vaccinium macrocarpon has historical use in North American traditional medicine, though specific duration or systems are not detailed for CranRichPAC. General cranberry species were traditionally used for urinary issues.

## Synergistic Combinations

D-mannose, vitamin C, [probiotic](/ingredients/condition/gut-health)s (Lactobacillus species), uva ursi

## Frequently Asked Questions

### What is CranRichPAC and how is it different from regular cranberry extract?

CranRichPAC is a standardized cranberry (Vaccinium macrocarpon) extract specifically characterized for its A-type proanthocyanidin (PAC) profile, with a defined composition of 49% tetramers and 37% pentamers. Unlike generic cranberry powders or juices, which have inconsistent and often unquantified PAC content, CranRichPAC is chemically analyzed to confirm the specific oligomeric structures believed responsible for anti-adhesion activity against E. coli. This standardization is considered important because only A-type PAC linkages, not the more common B-type found in grapes or cocoa, have demonstrated bacterial anti-adhesion properties in urinary tract research.

### How does CranRichPAC prevent urinary tract infections?

CranRichPAC does not kill bacteria directly; instead, its A-type proanthocyanidins coat the P-fimbriae of Escherichia coli, the hair-like appendages the bacteria use to grip uroepithelial cell receptors in the bladder and urinary tract. By blocking this mannose-resistant adhesion mechanism, the bacteria are more likely to be flushed out during urination rather than colonizing the tract and causing infection. It is important to note this mechanism has been validated in in vitro and some ex vivo models, and clinical translation to confirmed UTI prevention requires further proprietary clinical investigation.

### What is the recommended dosage of CranRichPAC for urinary health?

No officially established clinical dosage specific to CranRichPAC has been published in peer-reviewed trials. General cranberry extract research commonly uses doses standardized to 36 mg of PACs per day, a threshold cited in some European Food Safety Authority assessments as the minimum for potential anti-adhesion activity. Supplement manufacturers using CranRichPAC typically formulate products within this 36–72 mg PAC-per-day range, but consumers should verify the actual PAC content per serving on the product label rather than relying on total cranberry extract weight.

### Can CranRichPAC interact with blood thinners like warfarin?

Yes, cranberry products including concentrated extracts like CranRichPAC carry a documented interaction risk with warfarin (Coumadin). Cranberry constituents are believed to inhibit the cytochrome P450 enzyme CYP2C9, which is responsible for warfarin metabolism, potentially leading to elevated plasma warfarin levels and increased INR values with associated bleeding risk. The UK Medicines and Healthcare products Regulatory Agency (MHRA) issued warnings regarding this interaction, and patients on anticoagulant therapy should consult their physician before using any cranberry supplement.

### Is CranRichPAC safe to take every day long-term?

Short- to medium-term daily use of cranberry extracts at standard supplemental doses is generally considered safe for healthy adults based on available cranberry class data, with the primary reported adverse effects being mild GI upset at higher doses. Long-term safety data specifically for CranRichPAC as a branded ingredient is not available in published clinical literature. Individuals with recurrent kidney stones, particularly calcium oxalate stones, should use caution with chronic cranberry extract supplementation due to the potential for increased urinary oxalate excretion, and annual reassessment with a healthcare provider is a reasonable precaution.

### What is the bioavailability difference between CranRichPAC and other cranberry extract forms?

CranRichPAC is standardized for specific proanthocyanidin profiles (49% tetramers and 37% pentamers), which may offer more consistent absorption compared to non-standardized cranberry extracts that vary widely in PAC composition. The organic acid content (quinic, citric, and malic acids) in CranRichPAC may enhance bioavailability by supporting gastric pH conditions, though direct comparative absorption studies between CranRichPAC and other forms are limited. Standardized formulations like CranRichPAC typically provide more predictable clinical outcomes than whole fruit or unstandardized extracts.

### Is CranRichPAC safe for children or during pregnancy?

There is insufficient safety data specific to CranRichPAC use in children or during pregnancy, as most cranberry research has focused on adults with urinary tract concerns. While whole cranberries are generally recognized as safe food, concentrated extracts like CranRichPAC have not been adequately studied in these populations. Pregnant women and parents should consult a healthcare provider before using CranRichPAC supplementation.

### Does CranRichPAC have any other health benefits beyond urinary tract support?

CranRichPAC contains proanthocyanidins and organic acids with potential antioxidant activity based on chemical analysis, though clinical evidence for non-urinary health benefits in humans remains limited and largely indirect. General cranberry research suggests possible cardiovascular and oral health applications, but these have not been specifically validated for CranRichPAC as a branded ingredient. Most established clinical evidence for CranRichPAC focuses specifically on urinary tract health rather than broader wellness applications.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*